

# Results Presentation

## Fiscal 2022 First Quarter

協和キリン株式会社



**KYOWA KIRIN**

# Agenda

## Financial Review

Managing Executive Officer, Head of Finance **Motohiko Kawaguchi**

## Commercial Update

Executive Officer, Head of Global Product Strategy, Strategy Division **Tomohiro Sudo**

## R&D Update

Executive Officer, Head of R&D **Yoshifumi Torii, Ph.D.**

## News Flow in 2022

Managing Executive Officer, Head of Strategy Division **Takeyoshi Yamashita, Ph.D.**

## Q&A

Managing Executive Officer, Head of Strategy Division **Takeyoshi Yamashita, Ph.D.**

Managing Executive Officer, Head of Finance **Motohiko Kawaguchi**

Executive Officer, Head of R&D **Yoshifumi Torii, Ph.D.**

Executive Officer, Head of Global Product Strategy, Strategy Division **Tomohiro Sudo**

*This document contains certain forward-looking statements relating to such items as the company's (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but the actual results in practice may differ substantially due to uncertain factors.*

*These uncertain factors include, but are not limited to, potential risks of the business activities in the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, regulatory risks, product defect risks, risks of changes to the prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.*

*This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.*

# Financial Review

# Summary of Q1 Results


( Billion Yen / Rounded )

	2021Q1 Results	2022Q1 Results	Changes	2022 Plans	Progresses
Revenue <i>[Overseas Ratio]</i>	81.1 <i>[50%]</i>	87.8 <i>[58%]</i>	+6.6 (+8%)	380.0 <i>[59%]</i>	23%
Gross Profit <i>[Gross Profit Margin]</i>	58.7 <i>[72%]</i>	65.6 <i>[75%]</i>	+6.9 (+12%)	298.0 <i>[78%]</i>	22%
SG&A <i>[SG&amp;A Ratio]</i>	31.7 <i>[39%]</i>	36.1 <i>[41%]</i>	+4.4 (+14%)	164.0 <i>[43%]</i>	22%
R&D <i>[R&amp;D Ratio]</i>	12.2 <i>[15%]</i>	13.6 <i>[16%]</i>	+1.4 (+12%)	70.0 <i>[18%]</i>	19%
Gain/Loss on Equity Method	0.6	1.4	+0.8 (+126%)	3.0	48%
Core Operating Profit <i>[Core OP Margin]</i>	15.5 <i>[19%]</i>	17.3 <i>[20%]</i>	+1.8 (+12%)	67.0 <i>[18%]</i>	26%
Profit	12.9	16.0	+3.1 (+24%)	53.0	30%

\* We do not anticipate any direct impact to our business due to Russia/Ukraine conflict for a while, since we have not been operated in / purchased raw materials from those region.

# YoY Analysis -Revenue-

**+6.6 billion yen**  
(incl. forex effect +3.6)



## ● Japan -3.8

Although new products such as Duvroq and Crysvida increased, revenue in Japan decreased by JPY3.8B due mainly to negative impact by NHI price-cut in April 2021 and shrink in Patanol for which generic products entered the market last December.

## ● North America +4.8 (incl. forex effect +1.6)

Revenue in North America region increased by JPY4.8B with the growth of Crysvida, Poteligeo, and Nourianz.

## ● EMEA +2.5 (incl. forex effect +1.0)

Growth of Crysvida and Poteligeo contributed to the JPY2.5B increase in EMEA region, although Abstral fell due to generic products' penetration.

## ● APAC +0.4 (incl. forex effect +0.5)

APAC revenue increased by JPY0.4B with the growth of Gran, Neulasta, Nesp, etc, while Regpara was down due to the Chinese national tender system.

## ● Other +2.7 (incl. forex effect +0.5)

JPY2.7B growth in the other revenue was contributed by the royalties of Fasenna (Benralizumab) and deferred revenue of USD400M upfront payment from KHK4083 partnership that was initiated from last July.

# Revenue of Major Items (Japan)

( Billion Yen / Rounded )

Item	2021Q1 Results	2022Q1 Results	Changes	Reasons	2022 Plans	Progresses
Nesp + Nesp-AG <sup>*1</sup>	6.5	5.2	-1.2 (-19%)	NHI price-cut & Biosimilars' penetration	19.5	27%
Nesp	1.0	0.8	-0.1 (-13%)		3.1	27%
Nesp-AG	5.5	4.4	-1.1 (-20%)		16.4	27%
Duvroq	0.2	1.1	+0.9 (+570%)	Market penetration (Launched in Aug 2020)	5.5	20%
Regpara	0.7	0.5	-0.2 (-23%)		2.4	21%
Orkedia	2.1	2.2	+0.1 (+5%)		10.0	22%
G-Lasta	6.6	7.1	+0.5 (+8%)	Market's recovery & penetration	31.5	23%
Poteligeo	0.5	0.5	-0.0 (-1%)		1.9	24%
Rituximab BS	2.6	2.5	-0.1 (-4%)	NHI price-cut	9.7	26%
Romiplate	1.5	2.2	+0.7 (+44%)	Recovery from supply constraints since Jun 2020 through Mar 2021	10.0	22%
Allelock	2.9	2.4	- 0.5(-17%)	Generics' penetration & NHI price-cut	6.6	37%
Patanol	6.5	1.8	-4.7 (-72%)	Generics entered in Dec 2021	3.9	47%
Nourias	1.9	1.8	-0.1 (-7%)		8.4	21%
Haruropi	0.6	0.8	+0.2 (+38%)	Market penetration (Launched in Dec 2019)	5.5	14%
Crysvita	1.5	2.0	+0.5 (+31%)	Market penetration (Launched in Dec 2019)	10.0	19%
Tech-licensing	0.6	0.1	-0.5 (-81%)	Deferred process of FKB <sup>*2</sup> -related upfront revenue completed	1.0	12%

\*1 AG stands for Authorized Generic. Official product name is Darbeopetin Alfa [KKF]. Kyowa Kirin Frontier is a marketing authorization holder; Kyowa Kirin is a distributor.

\*2 FKB stands for Fujifilm Kyowa Kirin Biologics Co., Ltd.

# Revenue of Major Items (ex-Japan)

( Billion Yen / Rounded )

Item	2021Q1 Results	2022Q1 Results	Changes	Reasons	2022 Plans	Progresses
Crysvita	16.3	22.2	+6.0 (+37%)	[North America] Market penetration [EMEA] Geographical expansion & Additional indication (Adult) [APAC] Launched in China	105.2	21%
North America	11.7	15.8	+4.1 (+35%)			
EMEA	4.5	6.3	+1.8 (+40%)			
APAC	—	0.0	+0.0 (—)			
Poteligeo	3.2	4.2	+1.1 (+34%)	[North America] Market penetration [EMEA] Geographical expansion & Market penetration	22.5	19%
North America	2.6	3.3	+0.7 (+27%)			
EMEA	0.6	0.9	+0.4 (+67%)			
Nourianz	1.0	1.1	+0.2 (+19%)	Market penetration	6.6	17%
Abstral	1.8	1.4	-0.4 (-22%)	Generic's penetration	6.7	21%
Regpara	2.2	1.0	-1.3 (-56%)	Listed on Chinese tender list* <sup>1</sup> in Oct 2021	3.7	26%
Tech-licensing	4.9	7.7	+2.7 (+55%)	Deferred revenue of KHK4083 upfront payment (July 2021-) & Growth of Fasentra	34.3	22%
Benralizumab Royalty* <sup>2</sup>	3.8	4.7	+0.9 (+24%)			

\*1 Volume-Based Procurement (VBP) program that has been introduced since 2018 for reducing healthcare cost in China. A few companies are selected as a supplier through a tender, while their drug prices dramatically drop down.


\*2 Sales royalties of Fasentra which has been marketed by AstraZeneca, including our own estimation.

\* Revenue from Early Access Program (EAP) are not included in the figures above.



# YoY Analysis -Core OP-

**+1.8 billion yen  
(incl. forex effect +1.2)**



- **Gross Profit +6.9 (incl. forex effect +3.3)**

Increased in conjunction with JPY6.6B rise in revenue. Margin improved by 2.4% (72.4%→74.7%) because there was a big negative impact related to elimination of intercompany profits on inventories last year.

- **SG&A -4.4 (incl. forex effect -1.7)**

Increased by aggressive investment in IT/Digital infrastructure and human resources for the maximization of the global 3 brands (G3B) and the early consolidation of global business foundation, in addition to Crysvida profit sharing expenses for North America.  
[Labor -2.6 / Sales promotion -1.8 (incl. Crysvida profit sharing expenses -1.4) / Depreciation & Amortization +0.2 / Other -0.2]

- **R&D -1.4 (incl. forex effect -0.5)**

Clinical study cost of ME-401 and KHK4083/AMG 451, etc. increased.


- **Gain/Loss on Equity Method +0.8**

FKB recorded additional deferred tax asset.

\*FKB; Fujifilm Kyowa Kirin Biologics Co., Ltd.

# YoY Analysis -Profit-

**Profit (Jan-Mar) +3.1 billion yen**




# Commercial Update

# Crysvita



(Billion Yen)



\* Excludes EAP patients and patients who have not started reimbursement process

## 2022 Key Actions & 2022 Q1 Topics

### Key Actions

- North America : Initiate full-scale preparations for transfer of commercialization in spring 2023.
- EMEA : Continue to focus on geographical & indication expansion. TIO review to be completed.

### Q1 Topics

- North America : Negative impact from year-end load-up purchase by wholesalers. Preparations for the transfer are proceeding as planned.
- EMEA: Launched in Portugal for Peds, in France and Israel for Adults.
- Japan: Revenue is going as planned.

## Launched Countries/ Regions as of March 31, 2022

Excluding South America


Underlines: Pediatric and Adult /Bolded types: New launches in Q1 2022

- 2018 USA , Germany, Netherland, Luxembourg
- 2019 Canada, England, Wales, Northern Ireland, Slovakia, Sweden, **Israel**, UAE, Czech, Denmark, Italy, Japan, Norway, Bahrain, Australia
- 2020 Scotland, Oman, Kuwait, Qatar, Romania, Slovenia, **France**, Finland, Estonia, Spain
- 2021 Ireland, Hungary, Belgium, Saudi Arabia, Hong Kong, China, Singapore
- 2022 **Portugal**

# Poteligeo



(Billion Yen)



\* Excludes EAP patients and patients who have not started reimbursement process

## 2022 Key Actions & 2022 Q1 Topics

### Key Actions

- EMEA: Continue to talk with payers to ensure reimbursement and patient access to product.
- US/EMEA: Work with Healthcare professionals to gather and share evidence such as clinical data in association of blood tumor burden to help understand better use of Poteligeo.

### Q1 Topics

- EMEA: While reimbursement negotiations have been difficult and promotional activities have been restricted due to the COVID-19 pandemic, Poteligeo is growing steadily; Reimbursement agreed in France. Launch expected in Q2.

## Launched Countries/ Regions as of March 31, 2022

Bolded types: New launches in Q1 2022


- 2012 Japan
- 2018 USA
- 2020 Germany, Austria, Luxembourg
- 2021 Italy, Scotland, Netherland, Belgium, Slovenia, Denmark, Spain, Finland
- 2022 **Sweden, Saudi Arabia, Slovakia, England, Wales, Northern Ireland**

# Nourianz



**NOURIANZ**  
(istradefylline) tablets

(Billion Yen)



## 2022 Key Actions & 2022 Q1 Topics

### Key Actions

- North America: Focus on approaching potential prescribers and get their deeper understanding of the features of Nourianz such as safety, convenience, and novel mode of action.

### Q1 Topics

- North America: Increase in patients' out-of-pocket costs due to annual reset of Medicare and year-end load-up by pharmacies caused negative impacts; Actively holding lectures for HCPs/patients; F2F communication with HCPs on the rise; Advertisement/promotion via paid digital media.

## Launched Countries/ Regions as of March 31, 2022

2013 Japan  
2019 USA

# R&D Update

# Upcoming Events: Next-generation Strategic Products

Code Generic Name	Event	Time Expected	Month Completed
<b>KHK4083/AMG 451</b> rocatinlimab	Atopic dermatitis P3 FPI	Mid-2022	
<b>KW-6356</b>	Parkinson's disease P3 FPI Parkinson's disease P2b detailed data	H2 2022 H2 2022	
<b>ME-401</b> zandelisib	CLL (combo, 2L+) P2 FPI FL (mono, 3L+) P2 detailed data* iB-NHL (mono, 3L+) P2 topline data (JP)	H1 2022 Mid-2022 H2 2022	
<b>RTA 402</b> bardoxolone methyl	Diabetic kidney disease P3 LPO	H2 2022	
<b>KHK7791</b> tenapanor	Hyperphosphatemia under maintenance dialysis submission (JP)	H2 2022	

\*: a more complete report of the P2 TIDAL data reported on Nov. 30, 2021, to be provided; FPI: first patient in; LPO: last patient out; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; iB-NHL: indolent B-cell non-Hodgkin's lymphoma



# Update: Zandelisib US development plan

## ■ External Environment

- Several PI3K inhibitors have received accelerated approvals from the FDA based on data from single-arm studies in blood cancers.
- Around the end of 2021, several companies made a decision to withdraw their PI3K inhibitor indications/applications that had been marketed/applied for accelerated approvals following discussions with the FDA.
- Discussions at the FDA's Oncology Drug Advisory Committee in April 2022 concluded that randomized controlled trials should be conducted to assess the risk-benefit of the class of drugs in blood cancers.

## ■ Development Plan

- Kyowa Kirin and MEI Pharma were seeking accelerated approval of zandelisib using Phase 2 (TIDAL) study data in a single-arm design, similar to the preceding PI3K inhibitors.
- In March 2022, the FDA indicated that it does not recommend approval based solely on single-arm TIDAL data, so the companies will focus on the ongoing Phase 3 (COASTAL) study, which is a randomized controlled trial. In parallel, discussions with the FDA will continue.

# News Flow in 2022

# Year-to-date Key News Flow

AS of May 10, 2022

Category	Pub date	Region	Headline
ESG	Jan 11	Japan	Introduction of Renewable Energy “Aqua Premium” for its Fuji Research Park and CMC R&D Center
LCM	Jan 31	Japan	NDA submission of Topical Ophthalmic Mitomycin C Agent
ESG	Feb 3	Global	Formulation of Global DE&I Statement
LCM	Feb 25	Japan	Approval for Partial Change of Approved Indication of G-Lasta (for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogenic Blood Stem Cell Transplantation)
ESG	Mar 9	Japan	Selection for “Health & Productivity Stock” for the First Time
LCM	Mar 23	Japan	Approval for Partial Change of Approved Indication of Hysron Tablets 5
R&D	Mar 31	Global	Regulatory Update on Zandelisib Following Meeting with the FDA
LCM	Apr 4	Japan	Publication of Safety Data from a Clinical Trial of Automated Injection Device of G-Lasta

**Updates after the previous earnings announcement**

# Appendix

# FOREX Information

## Average FOREX Rates (yen)

	2021Q1	2022Q1	Changes	2022 Plans
USD/JPY	105	114	+9	110
GBP/JPY	143	154	+11	150

## Q1 YoY FOREX Impacts (billion yen)

	Revenue	Core OP
USD/JPY	+2.0	+0.6
GBP/JPY	+1.0	+0.2

## FY2022 FOREX Sensitivities (billion yen)

	Changes	Revenue	Core OP
USD/JPY	+1 yen	+1.1	+0.3
GBP/JPY	+1 yen	+0.4	+0.1

# Crysvita - Collaboration with Ultragenyx -

## Economic Terms

### US & Canada

- Kyowa Kirin books sales
- 50/50 profit share for 5 years from the U.S. launch
- After 5 years, Kyowa Kirin pays tiered sales royalties in mid-high 20% range to Ultragenyx
- Supply price: 35% of net sales through 2022, 30% thereafter

### Europe

- Kyowa Kirin books sales
- Kyowa Kirin pays sales royalties in up to 10% range to Ultragenyx  
\*Ultragenyx has sold a royalty right from 2020 onwards to Royalty Pharma

### Latin America

- Ultragenyx books sales
- Kyowa Kirin receives low single-digit sales royalties from Ultragenyx
- Supply price: 35% of net sales through 2022, 30% thereafter

### Turkey

- Ultragenyx books sales
- Kyowa Kirin receives sales royalties in up to 20% range from Ultragenyx

### Asia & Others

- Kyowa Kirin books sales

\* Kyowa Kirin supplies commercial products in all territories.

# KHK4083/AMG 451 - Collaboration with Amgen -

	<b>US</b>	<b>Europe &amp; Asia (ex. JP)</b>	<b>JP</b>
<b>Development</b>	<ul style="list-style-type: none"> <li>• Amgen leads development</li> <li>• Share development cost</li> </ul>	<ul style="list-style-type: none"> <li>• Amgen leads development</li> <li>• Share development cost</li> </ul>	<ul style="list-style-type: none"> <li>• Kyowa Kirin leads development</li> </ul>
<b>Commercialization</b>	<ul style="list-style-type: none"> <li>• Amgen commercializes and books sales</li> <li>• Kyowa Kirin co-promotes and shares promotion cost</li> </ul>	<ul style="list-style-type: none"> <li>• Amgen commercializes and books sales</li> <li>• Kyowa Kirin has opt-in rights for co-promotion</li> </ul>	<ul style="list-style-type: none"> <li>• Kyowa Kirin commercializes and books sales</li> </ul>
<b>Sales Royalties</b>	<ul style="list-style-type: none"> <li>• Double-digit royalty to Kyowa Kirin</li> </ul>	<ul style="list-style-type: none"> <li>• Double-digit royalty to Kyowa Kirin</li> </ul>	
<b>Commercial supply</b>	<ul style="list-style-type: none"> <li>• Amgen supplies</li> </ul>	<ul style="list-style-type: none"> <li>• Amgen supplies</li> </ul>	<ul style="list-style-type: none"> <li>• Kyowa Kirin supplies</li> </ul>

Amgen makes a \$400 million up-front payment (done) and future contingent milestone payments potentially worth up to an additional \$850 million, as well as royalty payments on future global sales, to Kyowa Kirin.

# Development Plan of Next-generation Strategic Products

**T** : Topline data

**D** : Detailed data

As of May 10, 2022

Code Generic Name	Target Disease		2022	2023	2024	+		
KHK4083/ AMG 451 rocatinlimab	Atopic dermatitis	P3	[Progress bar from 2022 to 2024]				ROCKET	
KW-6356	Parkinson's disease	P2b P3		[D]	[Progress bar from 2023 to 2024]			
ME-401 zandelisib	FL (mono, 3L+)	P2		[D**]	[Progress bar from 2023 to 2024]		} TIDAL	
	MZL (mono, 3L+)	P2	[Progress bar from 2022 to 2024]					COASTAL
	FL/MZL (combo, 2L+)	P3	[Progress bar from 2022 to 2024]					
	iB-NHL (mono, 3L+)*	P2		[T]	[Progress bar from 2023 to 2024]		MIRAGE	
	CLL (combo, 2L+)	P2	[Progress bar from 2022 to 2024]					
RTA 402 bardoxolone methyl	Alport syndrome	Filed						
	Diabetic kidney disease	P3	[Progress bar from 2022 to 2023]				AYAME	
	ADPKD	P3	[Progress bar from 2022 to 2024]				FALCON	
KHK7791 tenapanor	Hyperphosphatemia under maintenance dialysis	P3						
		P3		[MA*]				
		P3	[Progress bar from 2022 to 2023]					
		P3	[Progress bar from 2022 to 2023]					

\*: Japan; \*\*: a more complete report of the P2 TIDAL data reported on Nov. 30, 2021, to be provided; MA: marketing application; FL: follicular lymphoma; MZL: marginal zone lymphoma; iB-NHL: indolent B-cell non-Hodgkin's lymphoma; CLL: chronic lymphocytic leukemia; ADPKD: autosomal dominant polycystic kidney disease; 3L: third-line or later therapy ; 2L: second-line or later therapy



# Estimated Patient Numbers

Disease	Country/ Region	Incidence	Prevalence*	Reference
ATL	JP	1,150 / y		Survey and countermeasures to HTLV-1 infection and related diseases in Japan. 2009 summary research report (Yamaguchi, 2010)
PTCL	JP		2,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
CTCL	JP		2,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
	US	1,500 / y		SEER Data (2001-2007)
XLH	JP	1:20,000	Adult: 5,000 Ped: 1,000	Estimate based on reported prevalence of 1 in 20,000 people; Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. (Endo I et al., Endocr J., 2015)
	EU	1:20,000	Adult: 12,000 Ped: 3,000	Estimate based on reported prevalence of 1 in 20,000 people
	US	1:20,000	Adult: 12,000 Ped: 3,000	Estimate based on reported prevalence of 1 in 20,000 people; New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. (Carpenter TO, Pediatr Clin North Am., 1997)
TIO	JP		30	2010 Ministry of Health, Labour and Welfare Epidemiological Research on abnormalities in Hormone Receptor Mechanisms
	US		500-1,000	Survey by Ultragenyx Pharmaceutical
AD	JP, NA, EU		30,000,000	Study by Decision Resources
PD	JP		162,000	Ministry of Health, Labour and Welfare: 2017 Patient survey (illness classification)
	US	60,000 / y	~1,000,000	Cited from Parkinson's Foundation <a href="https://www.parkinson.org/Understanding-Parkinsons/Statistics">https://www.parkinson.org/Understanding-Parkinsons/Statistics</a> Accessed February 7, 2022.
FL	US	15,000 / y		Cited from Cancer.net <a href="https://www.cancer.net/">https://www.cancer.net/</a> Accessed February 7, 2022.
	JP	6,750 / y		Cited from Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry) and Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan (Miyoshi H et al., Int J Hematol, 2018)
MZL	US	6,000 / y		Cited from Lymphoma.org <a href="https://lymphoma.org/">https://lymphoma.org/</a> Accessed February 7, 2022.
	JP	1,060 / y		Cited from Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry) and Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan (Miyoshi H et al., Int J Hematol, 2018)
AS	JP		1,200	Cited from the website of Japan Intractable Diseases Information Center <a href="https://www.nanbyou.or.jp/entry/4348">https://www.nanbyou.or.jp/entry/4348</a> Accessed February 7, 2022.
ADPKD	JP		31,000	Cited from the website of Japan Intractable Diseases Information Center <a href="https://www.nanbyou.or.jp/entry/295">https://www.nanbyou.or.jp/entry/295</a> Accessed February 7, 2022.
CKD	JP		13,300,000	Japanese Society of Nephrology, Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease (2012)
CKD (Dialysis)	JP	40,885 / y	344,640	The Japanese Society for Dialysis Therapy, An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2019)

# List of Acronyms

AD	Atopic Dermatitis
ADPKD	Autosomal Dominant Polycystic Kidney Disease
AG	Authorized Generic
AS	Alport Syndrome
ATL	Adult T-Cell Leukemia/Lymphoma
BS	Biosimilar
CKD	Chronic Kidney Disease
CLL	Chronic Lymphocytic Leukemia
DKD	Diabetic Kidney Disease
FL	Follicular Lymphoma
iB-NHL	Indolent B-cell Non-Hodgkin's Lymphoma
LCM	Lifecycle Management
MZL	Marginal Zone Lymphoma
PD	Parkinson's Disease
PTCL	Peripheral T-Cell Lymphoma
TIO	Tumor Induced Osteomalacia
XLH	X-linked Hypophosphatemia



**Kyowa Kirin Co., Ltd.**  
**Corporate Communications Dept., IR Group**  
**+81-3-5205-7206 / [ir@kyowakirin.com](mailto:ir@kyowakirin.com)**